Isatuximab
Extranodal Nasal NK/T Cell Lymphoma
Won Seog Kimmonoclonal_antibodyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
50 Active assets in the Extranodal Nasal NK/T Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pegaspargase CStone Pharmaceuticals | Phase 4 | BBB |
Dexasone Mingzhi Zhang | Phase 4 | BBB |
Cis-Diamminedichloroplatinum Ii National Cancer Centre, Singapore | Phase 4 | BBB |
Tucidinostat Ruijin Hospital | Phase 4 | BB |
Etoposide Tarapeutics Science Inc. | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Isatuximab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →